📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-10 17:12
1 analysed today
FollowTelegram
1
Today
151,860
All-time analysed
43,535
Positive
6,743
Negative
92,745
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Kimia Biosciences Q1 Revenue Drops 12% YoY to ₹20.72 Cr; Reports Comprehensive Loss
Kimia Biosciences reported a weak performance for Q1 FY27, with revenue from operations declining 12.1% YoY to ₹20.72 Cr. While the company posted a marginal Net Profit of ₹0.36 Cr, it recorded a Total Comprehensive Loss of ₹0.11 Cr due to negative adjustments in other comprehensive income. Sequentially, revenue saw a sharp contraction of 23.8% compared to the March 2026 quarter. The company continues to operate with high leverage, evidenced by a debt-to-equity ratio of 1.94.
Confidence: HIGH
What changedThe company has transitioned from a total comprehensive profit in the previous year to a comprehensive loss this quarter, alongside a double-digit decline in revenue.
Why it mattersFor a small-cap company with a market cap of ₹141 Cr, declining revenues and high leverage (Debt of ₹35 Cr vs Net Worth of ₹18 Cr) significantly increase financial risk and limit expansion capabilities.
Revenue (Q1 FY27): ₹20.72 CrYoY Revenue Growth: -12.1%Total Comprehensive Income: -₹0.11 CrDebt-to-Equity Ratio: 1.94Promoter Holding: 74.94%
📅 Short termThe stock may face downward pressure in the short term due to the revenue contraction and the reporting of a comprehensive loss.
📈 Long termThe long-term outlook remains cautious unless the company demonstrates a clear path to debt reduction and sustainable revenue growth in the competitive pharmaceutical sector.
⚠ Risk flags
- High Debt-to-Equity ratio (1.94)
- Declining revenue trend (YoY and QoQ)
- Negative Total Comprehensive Income
- High raw material cost concentration
Key Highlights
Revenue from operations fell 12.1% YoY to ₹20.72 Cr from ₹23.58 Cr in the previous year's corresponding quarter.
Net Profit for the quarter stood at ₹0.36 Cr, down 17% from ₹0.43 Cr in Q1 FY26.
Total Comprehensive Income turned negative at -₹0.11 Cr due to a ₹0.46 Cr loss in remeasurement of defined benefit plans.
Cost of materials consumed remained high at ₹16.57 Cr, representing 80% of revenue from operations.
Earnings Per Share (EPS) for the quarter was ₹0.08, compared to ₹0.13 in the year-ago period.
👀 What to Watch
Investors should monitor the company's ability to stabilize its top-line growth and manage its high debt-to-equity ratio of 1.94, which poses a risk in a high-interest-rate environment.
Rs 20.72 Cr Revenue in Q1 FY27; Net Profit Declines 17% YoY
Kimia Biosciences reported a weak start to FY27, with Q1 revenue declining 12.1% YoY to Rs 20.72 Cr compared to Rs 23.58 Cr in Q1 FY26. Net profit for the quarter stood at Rs 0.36 Cr, a 17% decrease from Rs 0.43 Cr in the same period last year. Sequentially, the performance was even more subdued, with revenue dropping 23.8% from Rs 27.20 Cr in Q4 FY26. The company maintains a high debt-to-equity ratio of 1.94, making the top-line contraction a point of concern for debt servicing.
Confidence: HIGH
What changedThe company released its unaudited financial results for the quarter ended June 30, 2026, showing a contraction in business scale compared to both the previous year and the previous quarter.
Why it mattersFor a micro-cap pharmaceutical company with a market cap of Rs 141 Cr, consistent revenue growth is critical to support its high valuation (P/B of 7.8) and manage its debt obligations.
Revenue (Q1 FY27): Rs 20.72 CrNet Profit (Q1 FY27): Rs 0.36 CrYoY Revenue Growth: -12.1%QoQ Revenue Growth: -23.8%Finance Cost: Rs 0.83 Cr
📅 Short termThe stock may face downward pressure in the short term as the market reacts to the double-digit decline in revenue and the year-on-year drop in profitability.
📈 Long termLimited structural significance unless the company can demonstrate a clear path to scaling its pharmaceutical operations and reducing its leverage.
⚠ Risk flags
- High Debt-to-Equity ratio (1.94)
- Declining revenue trend (YoY and QoQ)
- Thin net profit margins
Key Highlights
Revenue from operations decreased to Rs 20.72 Cr, down 12.1% from Rs 23.58 Cr in the year-ago quarter.
Net profit for Q1 FY27 was Rs 0.36 Cr, compared to Rs 0.43 Cr in Q1 FY26.
Total expenses were reduced to Rs 20.31 Cr from Rs 23.74 Cr YoY, primarily due to lower material costs.
Finance costs remained relatively stable at Rs 0.83 Cr, accounting for 4% of total revenue.
Earnings Per Share (EPS) for the quarter remained flat at Rs 0.08 compared to the immediate previous quarter.
👀 What to Watch
Investors should monitor the company's ability to stabilize its top-line growth and improve operating margins, which are currently under pressure. The high debt-to-equity ratio (1.94) requires close attention to interest coverage in future quarters.
